Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ENLV |
---|---|---|
09:32 ET | 2788 | 1.4 |
09:36 ET | 432 | 1.4 |
09:38 ET | 100 | 1.42 |
10:12 ET | 411 | 1.4204 |
10:15 ET | 2408 | 1.4202 |
10:17 ET | 1100 | 1.42 |
10:33 ET | 200 | 1.42 |
10:37 ET | 100 | 1.4 |
10:39 ET | 100 | 1.405 |
11:00 ET | 200 | 1.405 |
11:02 ET | 100 | 1.405 |
11:08 ET | 500 | 1.4 |
11:11 ET | 200 | 1.395 |
11:22 ET | 3845 | 1.385 |
11:26 ET | 2300 | 1.39 |
11:27 ET | 100 | 1.385 |
11:31 ET | 1006 | 1.39 |
11:51 ET | 3813 | 1.4 |
12:16 ET | 100 | 1.4 |
12:18 ET | 100 | 1.395 |
12:25 ET | 800 | 1.4 |
12:27 ET | 2099 | 1.4 |
12:30 ET | 100 | 1.4 |
12:34 ET | 300 | 1.4 |
01:30 ET | 200 | 1.4 |
01:35 ET | 300 | 1.4 |
01:39 ET | 100 | 1.39 |
02:00 ET | 200 | 1.4 |
02:06 ET | 400 | 1.4 |
02:22 ET | 400 | 1.396 |
02:27 ET | 100 | 1.396 |
02:31 ET | 800 | 1.41 |
02:33 ET | 380 | 1.41 |
02:36 ET | 100 | 1.405 |
02:38 ET | 300 | 1.41 |
02:49 ET | 100 | 1.41 |
02:58 ET | 150 | 1.41 |
03:05 ET | 3091 | 1.41 |
03:07 ET | 396 | 1.44 |
03:12 ET | 742 | 1.41 |
03:34 ET | 301 | 1.44 |
03:52 ET | 2400 | 1.43 |
03:56 ET | 1000 | 1.4479 |
03:59 ET | 200 | 1.42 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Enlivex Therapeutics Ltd | 26.7M | -0.9x | --- |
Biora Therapeutics Inc | 26.2M | -0.1x | --- |
Bioxytran Inc | 25.5M | -4.9x | --- |
Eom Pharmaceutical Holdings Inc | 28.1M | -5.7x | --- |
Apollomics Inc | 28.4M | -0.1x | --- |
NanoViricides Inc | 24.9M | -2.6x | --- |
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.